ZION
68
3
CVS
57
7
DNB
84
2
CVX
40
-7
FE
52
2
FTI
79
-2
MNST
56
4
TAP
61
3
AMT
42
3
RL
78
6
PEP
50
2
HSIC
59
3
COP
44
-9
IBM
61
3
OMC
64
2
HPE
50
-13
K
59
2
EMC
59
6
CRM
65
-2
OXY
38
-4
ZION
68
3
CVS
57
7
DNB
84
2
CVX
40
-7
FE
52
2
FTI
79
-2
MNST
56
4
TAP
61
3
AMT
42
3
RL
78
6
PEP
50
2
HSIC
59
3
COP
44
-9
IBM
61
3
OMC
64
2
HPE
50
-13
K
59
2
EMC
59
6
CRM
65
-2
OXY
38
-4
Financhill
Back

Cartesian Therapeutics 10K Form

Sell
34

RNAC
Cartesian Therapeutics

Last Price:
18.29
Seasonality Move:
13.13%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive RNAC News And Ratings

See the #1 stock for the next 7 days that we like better than RNAC

RNAC Financial Statistics

Sales & Book Value

Annual Sales: $26M
Cash Flow: $7.49M
Price / Cash Flow: 0
Annual Sales: $0.03
Price / Book: 605.29

Profitability

EPS (TTM): -54.95000
Net Income (TTM): $-244.83M
Gross Margin: --
Return on Equity: 0%
Return on Assets: -79.52%

Cartesian Therapeutics Earnings Forecast

Key Cartesian Therapeutics Financial Ratios

  • The Research & Development expenses have been 276.26% of Revenue.
  • The Interest Expense is -1.29% of Operating Income.
  • The Net Earning history of RNAC is -844.91% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 6 years.

Cartesian Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: RNAC
Website: cartesiantherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 10.7
Quick Ratio: 10.51

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RNAC Technical Analysis vs Fundamental Analysis

Sell
34
Cartesian Therapeutics (RNAC) is a Sell

Is Cartesian Therapeutics a Buy or a Sell?